Table 2.
Risk ratios for postmenopausal estrogen receptor-positive breast cancer per doubling of biomarker concentration
| Biomarker (per doubling concentration) | Cases | Subcohort Non-Cases | Risk Ratio | 95% CI |
|---|---|---|---|---|
| Progesterone (nmol/L) | ||||
| Primary analysis | 342 | 865 | 1.22 | (1.03, 1.44) |
| Androstenedione (nmol/L) | ||||
| Primary analysis | 342 | 866 | 1.20 | (0.99, 1.45) |
| DHEA (nmol/L) | ||||
| Primary analysis | 342 | 866 | 1.15 | (1.00, 1.34) |
| Total Testosterone (nmol/L) | ||||
| Primary analysis (adjusted for SHBG) | 342 | 866 | 1.11 | (0.96, 1.29) |
| Not adjusted for other biomarkers | 342 | 866 | 1.10 | (0.95, 1.27) |
| Free Testosterone (nmol/L) | ||||
| Primary analysis | 342 | 866 | 1.12 | (0.98, 1.28) |
| Estrone (pmol/L) | ||||
| Primary analysis (adjusted for adiponectin, leptin, TNF-α, IL-6, insulin, IGF-1 and SHBG) | 342 | 863 | 1.21 | (0.99, 1.48) |
| Not adjusted for other biomarkers | 342 | 864 | 1.20 | (0.98, 1.45) |
| Total Estradiol (pmol/L) | ||||
| Primary analysis (adjusted for adiponectin, leptin, TNF-α, IL-6, insulin, IGF-1 and SHBG) | 341 | 858 | 1.19 | (1.02, 1.39) |
| Not adjusted for other biomarkers | 341 | 859 | 1.20 | (1.04, 1.38) |
| Free Estradiol (pmol/L) | ||||
| Primary analysis (adjusted for adiponectin, leptin, TNF-α, IL-6, insulin and IGF-1) | 341 | 858 | 1.22 | (1.05, 1.41) |
| Not adjusted for other biomarkers | 341 | 859 | 1.18 | (1.03, 1.35) |
| SHBG (nmol/L) | ||||
| Primary analysis (adjusted for adiponectin, leptin, insulin and IGF-1) | 342 | 865 | 0.83 | (0.66, 1.05) |
| Not adjusted for other biomarkers | 342 | 866 | 0.90 | (0.73, 1.11) |
CI: Confidence interval. DHEA: Dehydroepiandrosterone. SHBG: Sex hormone binding globulin. IGF-1: Insulin-like growth factor-1. IL-6: Interleukin-6. TNF-α: Tumor necrosis factor-alpha. nmol/L: Nanomoles per liter. pmol/L: Picomoles per liter.
The results of the primary analyses were adjusted for sociodemographic and lifestyle confounders (education, socioeconomic disadvantage, Southern European Migrant status, dietary intake of carotenoids at baseline, dietary intake of calcium at baseline, lifestyle alcohol consumption at baseline, smoking status at baseline, adiposity at baseline, physical activity at the second follow-up wave and age at blood collection) and other biomarkers identified as potential confounders, where applicable (Online Resource 8).